12:00 AM
Feb 02, 2009
 |  BC Week In Review  |  Company News  |  Deals

CV Therapeutics, Astellas deal

Astellas revived an unsolicited bid it originally made in November to acquire CV Therapeutics for $16 per share, or about $1 billion in cash. CV's board rejected the initial offer. The price is a 41% premium to CV's close of $11.35 on Jan. 26, before...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >